ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,007.68
1.10%
US Tech 100
21,089.20
1.67%
다우존스 지수
42,975.32
0.57%
Bitcoin
101,876.98
3.61%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. AMEX

  6. Hemispherx Biopharma Inc New (HEB) 시세

Hemispherx Biopharma Inc New

Hemispherx Biopharma Inc New (HEB)

Hamilton Canadian Bank Equal Weight Index ETF
1.80
0.00
( 0.00% )
업데이트: 09:00:00
15분 지연

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

프리미엄

주요 통계 및 세부정보

가격
1.80
매수가
-
매도가
-
거래량
-
0.00 일간 변동폭 0.00
0.00 52주 범위 0.00
market_cap
87.916M
전일 종가
1.80
개장가
-
최근 거래 시간
마지막 거래 시간
-
재정 규모
-
VWAP
-
평균 볼륨(3m)
-
발행 주식
48,842,000
배당수익률
-
주가수익률
-3.04
주당순이익(EPS)
-0.59
매출
202k
순이익
-28.96M

Hemispherx Biopharma Inc New 정보

Hemispherx Biopharma Inc is a US-based specialty pharmaceutical company. It is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune-based disorders. The products of the firm are Alferon N Injection and the e... Hemispherx Biopharma Inc is a US-based specialty pharmaceutical company. It is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune-based disorders. The products of the firm are Alferon N Injection and the experimental therapeutic Ampligen. Alferon N Injection is approved for a category of STD infection, and Ampligen represents a RNA being developed for viral diseases and disorders of the immune system. The sales revenue of the company is derived from the United States. 더 보기

섹터
Biological Pds,ex Diagnstics
산업
Biological Pds,ex Diagnstics
웹사이트
www.aimimmuno.com
본부
Wilmington, Delaware, USA
설립됨
-

HEB 최신 뉴스

추가 뉴스

Hemispherx Biopharma, Inc. Changes Name to AIM ImmunoTech Inc. Reflecting Ampligen’s® Immuno Modulation Progress in Ongoin...

OCALA, Fla., Aug. 23, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-tech company focused on the research and development of immunological agents to treat...

23 8월 2019
GlobeNewswire Inc.

Hemispherx Issues 2019 Second Quarter Report Citing Strong Steady Progress in Cancer Clinical Trials

OCALA, Fla., Aug. 15, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple...

15 8월 2019
GlobeNewswire Inc.

Hemispherx Reports Positive Safety and Survival Data in Phase 1 Stage 4 Ovarian Cancer Clinical Study Using Ampligen®

OCALA, Fla., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE American: HEB) announced today that the University of Pittsburgh Medical Center (UPMC) has issued a final report...

08 8월 2019
GlobeNewswire Inc.

Hemispherx Secures Corrections from Two Stock News Organizations Related to Their Inaccurate Reporting of an Equity Distribut...

OCALA, Fla., Aug. 02, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE American: HEB) recently demanded and received retractions and corrections in two cases of inaccurate reporting due to AI...

02 8월 2019
GlobeNewswire Inc.

Hemispherx Biopharma CFO Adam Pascale Announces Retirement

OCALA, Fla., June 28, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) announced today that Adam Pascale is retiring from the position of Chief Financial Officer after...

28 6월 2019
GlobeNewswire Inc.

Hemispherx Biopharma Issues Clinical Update for Ampligen Immuno-oncology Program

OCALA, Fla., June 17, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma Inc. (NYSE American: HEB) issued its quarterly update on the progress of its ongoing clinical trials evaluating Ampligen’s...

17 6월 2019
GlobeNewswire Inc.

Hemispherx Biopharma Announces First Patient Treated in Phase 2 Ovarian Cancer Clinical Trial Evaluating Ampligen in Combinat...

OCALA, Fla., June 12, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma Inc. announced today that the first patient has been treated in the Phase 2 recurrent ovarian cancer...

13 6월 2019
GlobeNewswire Inc.

Hemispherx Biopharma Stockholders Approve Reverse Stock Split

OCALA, Fla., May 31, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple...

31 5월 2019
GlobeNewswire Inc.

Hemispherx Reports 2019 First Quarter Financial Results

OCALA Fla., May 16, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple...

16 5월 2019
GlobeNewswire Inc.

Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center Edges Closer for Hemispherx Biopharma

ORLANDO, FL, May 13, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Hemispherx Biopharma Inc., (NYSE American: HEB), an immuno-pharma company focused on the research and development of...

14 5월 2019
GlobeNewswire Inc.
기간변동변동 %시가고가저가평균 일일 거래량VWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

HEB - Frequently Asked Questions (FAQ)

What is the current Hemispherx Biopharma share price?
The current share price of Hemispherx Biopharma is US$ 1.80
How many Hemispherx Biopharma shares are in issue?
Hemispherx Biopharma has 48,842,000 shares in issue
What is the market cap of Hemispherx Biopharma?
The market capitalisation of Hemispherx Biopharma is USD 87.92M
What is the 1 year trading range for Hemispherx Biopharma share price?
Hemispherx Biopharma has traded in the range of US$ 0.00 to US$ 0.00 during the past year
What is the PE ratio of Hemispherx Biopharma?
The price to earnings ratio of Hemispherx Biopharma is -3.04
What is the cash to sales ratio of Hemispherx Biopharma?
The cash to sales ratio of Hemispherx Biopharma is 439.02
What is the reporting currency for Hemispherx Biopharma?
Hemispherx Biopharma reports financial results in USD
What is the latest annual turnover for Hemispherx Biopharma?
The latest annual turnover of Hemispherx Biopharma is USD 202k
What is the latest annual profit for Hemispherx Biopharma?
The latest annual profit of Hemispherx Biopharma is USD -28.96M
What is the registered address of Hemispherx Biopharma?
The registered address for Hemispherx Biopharma is 251 LITTLE FALLS DRIVE, NEW CASTLE, WILMINGTON, DELAWARE, 19808
What is the Hemispherx Biopharma website address?
The website address for Hemispherx Biopharma is www.aimimmuno.com
Which industry sector does Hemispherx Biopharma operate in?
Hemispherx Biopharma operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
RHERegional Health Properties Inc
US$ 4.3713
(182.02%)
32.92M
SBEVSplash Beverage Group Inc
US$ 0.3289
(37.16%)
41.42M
SSYSunlink Health Systems
US$ 1.11
(21.98%)
1.48M
EXODExodus Movement Inc
US$ 39.00
(19.23%)
19.16k
MITQMoving iMage Technologies Inc
US$ 0.76
(19.18%)
264.33k
AEONAEON Biopharma Inc
US$ 0.1748
(-69.28%)
31.49M
AMBOAmbow Education Holding Ltd
US$ 2.41
(-13.62%)
23.25k
LODEComstock Inc
US$ 0.584134
(-13.31%)
8.8M
SOXSDirexion Daily Semiconductor Bear 3X Shares New
US$ 18.04
(-11.61%)
25.26M
SYNXSilynxcom Ltd
US$ 4.4115
(-11.42%)
53.54k
SBEVSplash Beverage Group Inc
US$ 0.3289
(37.16%)
41.42M
SOXLDirexion Daily Semiconductor Bull 3X Shares
US$ 33.35
(11.84%)
39.87M
RHERegional Health Properties Inc
US$ 4.3713
(182.02%)
32.92M
AEONAEON Biopharma Inc
US$ 0.1748
(-69.28%)
31.49M
SOXSDirexion Daily Semiconductor Bear 3X Shares New
US$ 18.04
(-11.61%)
25.26M

HEB Discussion

게시물 보기
mick mick 4 년 전
Hemispherx Biopharma (HEB)
1.8 ? 0.0 (0.00%)
Volume: 0 @-
Bid Ask Day's Range
- - - - -
HEB Detailed Quote
👍️0
Richard2 Richard2 4 년 전
I liked the original name better lol. Still think this drug has great potential, but I’m disappointed there wasn’t any news from the Japan trials.
👍️0
mick mick 5 년 전
Hemispherx Biopharma (HEB) NOW AIM
👍️0
deniseann deniseann 5 년 전
Thank you Richard, I couldn't seem to find anything on the change...
👍️0
Richard2 Richard2 5 년 전
‘AIM’ is the new ticker.
👍️0
Richard2 Richard2 5 년 전
No, the company changed its name and ticker. There’s a new board.
👍️0
deniseann deniseann 5 년 전
Is this still a real stock..?
👍️0
lowfloatwayne lowfloatwayne 5 년 전
Buying all i can it may be a long haul there is probably a reason they taking shares instead of all their pay. Hopefully a buy out.
👍️0
Richard2 Richard2 5 년 전
This drug could be huge in the me/cfs community, I really thought it would’ve received approval here in the states.
👍️0
LW89 LW89 5 년 전
They need cash so they can hit their finish and fill due in October...and they need to poly-line recertified for that to happen. They are still planning to send product to Argentina (filed the paperwork) - so regardless of what they in their PRs...someone in management is still pursuing ME/CFS where they have approvals to build on.
👍️0
lowfloatwayne lowfloatwayne 5 년 전
Their voting now to raise the share count from 2018
👍️0
lowfloatwayne lowfloatwayne 5 년 전
Acusphere has twice as many shares moves ez this should rocket eiyh the right hedge or buy out merger
👍️0
cspratt15139 cspratt15139 5 년 전
this is just sad. pure sad
👍️0
lowfloatwayne lowfloatwayne 5 년 전
Ok their not adding shares could be a 2008 run cant tell whats bottom they bought in at 2.30? Legally
👍️0
cspratt15139 cspratt15139 5 년 전
they do this to themselves
👍️0
lowfloatwayne lowfloatwayne 5 년 전
So they rs to 2.2m shares then dilute 70m shares https://seekingalpha.com/article/893871-tracking-recent-buy-calls-and-investments-by-the-maxim-group
I hope the can run a pump and dump and clay can do a video.
👍️0
aristotelisonassis aristotelisonassis 5 년 전
strong buy here. Bottom bouncer.
👍️0
cspratt15139 cspratt15139 6 년 전
Hope everyone is enjoying there weekend. Stay safe and blessed!
👍️0
cspratt15139 cspratt15139 6 년 전
Ampligen is picking up steam
👍️0
bleu22 bleu22 6 년 전
Fully funded trial up to 45-people, low float, looking for large pharmaceutical partnership, and more news on the way... I’m in. GLTA
👍️0
cspratt15139 cspratt15139 6 년 전
Going higher
👍️0
420man 420man 6 년 전
LOL..Can't even wait a few days to reward their Tutes via PR! And that's even after crushing retail for months. They will continue dumping all the way down helping shorty... I need to start shorting these plays. So damn predictable.
👍️0
bleu22 bleu22 6 년 전
They don’t even have options laid out yet. WTF
👍️0
whytestocks whytestocks 6 년 전
News: $HEB Hemispherx Biopharma Announces First Patient Treated in Phase 2 Ovarian Cancer Clinical Trial Evaluating Ampligen in Combination with Pembrolizumab and Cisplatin

OCALA, Fla., June 12, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma Inc. announced today that the first patient has been treated in the Phase 2 recurrent ovarian cancer program at the University of Pittsburgh Medical Center (UPMC) (See: https://clinicaltrials...

In case you are interested https://marketwirenews.com/news-releases/hemispherx-biopharma-announces-first-patient-treated-in-phase-2-ovarian-cancer-clinical-trial-evaluating-ampligen-in-combination-with-pembrolizumab-and-cisplatin-8346632.html
👍️0
420man 420man 6 년 전
There's your RS... Let the shorting begin!!!
👍️0
cspratt15139 cspratt15139 6 년 전
Split coming
👍️0
420man 420man 6 년 전
.05
👍️0
Golden Cross Golden Cross 6 년 전
How low will it go before the RS is the question? I am staying out wish all GL
👍️0
whytestocks whytestocks 6 년 전
News: $HEB Hemispherx Biopharma Stockholders Approve Reverse Stock Split

OCALA, Fla., May 31, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, today announced that its stockholders voted in...

Read the whole news https://marketwirenews.com/news-releases/hemispherx-biopharma-stockholders-approve-reverse-stock-split-8277778.html
👍️0
cspratt15139 cspratt15139 6 년 전
When is the rs
👍️0
hebbeke47 hebbeke47 6 년 전
https://www.mrknewsroom.com/news-release/oncology/merck-provides-update-phase-3-keynote-119-study-keytruda-pembrolizumab-monothe
👍️0
carldfw carldfw 6 년 전
They have investors after the rs or people to buy in. They have been selling out with each pump. Hope they have a ringer in the fda. Or 10 years later the same pumps as 2008
👍️0
Golden Cross Golden Cross 6 년 전
HEB Daily Chart:

👍️0
whytestocks whytestocks 6 년 전
News: $HEB Hemispherx Links Stanford's ME/CFS Diagnostic to a Potential Path Forward for Ampligen Commercialization

OCALA, Fla., May 06, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma Inc., (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases — and whose product portfolio includes Amp...

In case you are interested https://marketwirenews.com/news-releases/hemispherx-links-stanford-s-me-cfs-diagnostic-to-a-potential-path-forward-for-ampligen-commercialization-8123236.html
👍️0
Golden Cross Golden Cross 6 년 전
HEB on High Alert
👍️0
tknuncle tknuncle 6 년 전
WOW that's insane!!!! Thanks for sharing the actual numbers ;)
👍️0
420man 420man 6 년 전
So the warrant exercise price has been reduced to .15?! These guys are sucker punching retail! They would be delisted already if they traded on the the NAZ. JMO

The following table illustrates the dilution:

Offering price per share $0.15
Net tangible book value per share as of December 31, 2018 $(0.0875 )
Increase in net tangible book value per share after this offering $(0.0041)
Pro forma net tangible book value per share after this offering $(0.916 )

Dilution per share to the investor in this offering $0.0584
👍️0
pberger pberger 6 년 전
As I said several times, no value here, but pure CRAP.
👍️0
ClayTrader ClayTrader 6 년 전
* * $HEB Video Chart 05-02-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
Golden Cross Golden Cross 6 년 전
sinking fast here
👍️0
nokomis nokomis 6 년 전
price of warrants reduced to .15 bearish
👍️0
pberger pberger 6 년 전
This pure CRAP is now below the "good news" from 2 days ago, such a TURD!!!
👍️0
Golden Cross Golden Cross 6 년 전
Nasty... Looking to buy back in on a big dip today
👍️0
ClayTrader ClayTrader 6 년 전
* * $HEB Video Chart 05-01-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
Golden Cross Golden Cross 6 년 전
Nice news today!
👍️0
Zarate69 Zarate69 6 년 전
Dilution pure....
👍️0
tknuncle tknuncle 6 년 전
Where are all these shares coming from? It seems we have gone through all the OS after yesterday and this morning. We don't know what the float is but reading the OS at the OTC. So again were are all these shares coming from? The flippers have to be out now. Are the Shares being shorted by
the MM's? Again too new to trading to know what is going on with HEB..I would appreciate any input ;)
👍️0
aidytrader aidytrader 6 년 전
Where is the news? Thanks
👍️0
TommyBoyTrader9460 TommyBoyTrader9460 6 년 전
$heb..huge news out today..shorts scrambling premarket...
👍️0
JJGl JJGl 6 년 전
26s!!
👍️0

최근 히스토리

AMEX
HEB
Hemispherx Biopharma
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유